Australia-based MindBio Therapeutics Corp., an ex-subsidiary to Blackhawk Corp. received ethics approval for a Phase 2 clinical trial assessing the effects of LSD microdoses, paired with meaning-centered psychotherapy, on patients with advanced-stage cancer.
The randomized, double-blind, placebo-controlled study follows positive outcomes from a Phase 1 trial on healthy volunteers including increases in energy, social connectivity, creativity, wellness and happiness as well as tolerance to the LSD microdoses.
CEO Justin Hanka said the clinical data collected so far has exceeded the company’s expectations and …